Balanced news tone
News Sentiment
OCGN sentiment intelligence
Ocugen Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
55
Balanced news tone
61 relevant articles
News tone and price action are not far from neutral.
82/100 classification confidence.
directly relevant articles
high-authority source matches
-2.6% over one week, +21.5% over four weeks, trend inactive, and materially above fair value.
Ocugen Inc. stock rises Tuesday, outperforms market
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
82/100 classification
One-week reaction
-2.6%
Price reacting lower
Trend fit
Trend inactive
21.5% over four weeks
Fair value
35.3%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
22
Neutral
31
Negative
8
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Zacks
Direct company coverage
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 15:50
- Source
- Zacks
Stock Titan
Direct company coverage
Ocugen (NASDAQ: OCGN) CFO assumes principal accounting role
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 07:00
- Source
- Stock Titan
Ad Hoc News
Direct company coverage
Ocugen Inc stock (US67577C1053): conference schedule and pre-market moves in focus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Ad Hoc News
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Ad Hoc News
Direct company coverage
Ocugen stock (US67577C1053): Q1 2026 earnings miss sparks stock drop
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 12 May 2026 07:00
- Source
- Ad Hoc News
Investing.com
Direct company coverage
Earnings call transcript: Ocugen Q1 2026 earnings miss triggers stock drop
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Investing.com
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Ocugen (OCGN) Is Down 16.8% After Convertible Notes Deal Extends Cash Runway - What's Changed
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 09 May 2026 07:00
- Source
- simplywall.st
Market source
Direct company coverage
Ocugen (OCGN) Is Down 16.8% After $115M Convertible Notes Deal And Wider Q1 Losses Has The Bull Case Changed?
- Tone
- Negative 34/100
- Event
- Deals and strategy
- Published
- 08 May 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Ocugen (OCGN) Valuation Check As Loss-Making Q1 2026 And US$103.5m Convertible Notes Reset Expectations
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 May 2026 07:00
- Source
- simplywall.st
Ocugen, Inc.
Direct company coverage
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Ocugen, Inc.
Market source
Direct company coverage
Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 May 2026 07:00
- Source
- Market source
Ocugen, Inc.
Direct company coverage
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 07:00
- Source
- Ocugen, Inc.
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
Ocugen sends executives to biotech meetings in Puerto Rico and Rome
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Apr 2026 07:00
- Source
- Stock Titan
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Apr 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Ocugen Hits Key Milestone In GARDian3 Stargardt Gene Therapy Program
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Apr 2026 07:00
- Source
- simplywall.st
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
simplywall.st
Direct company coverage
Is Ocugen (OCGN) Pricing Make Sense After Its Volatile Multi‑Year Share Price Swings
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Mar 2026 07:00
- Source
- simplywall.st
Stocktwits
Direct company coverage
OCGN Stock Tanks After Gene Therapy Trial Update — What Did Ocugen Announce?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Mar 2026 07:00
- Source
- Stocktwits
Market source
Direct company coverage
Ocugen (OCGN) Has A Healthy Cash Position For 2026
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 24 Mar 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Is It Too Late To Consider Ocugen (OCGN) After Its Recent Share Price Surge
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Mar 2026 07:00
- Source
- Market source
Market source
Direct company coverage
How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Mar 2026 07:00
- Source
- Market source
TradingView
Direct company coverage
Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 Dec 2025 08:00
- Source
- TradingView
simplywall.st
Direct company coverage
Ocugen (OCGN): Valuation Pressures Challenge Bullish Narrative as Profitability Remains Elusive
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 06 Nov 2025 08:00
- Source
- simplywall.st
Ocugen, Inc.
Direct company coverage
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Aug 2025 07:00
- Source
- Ocugen, Inc.
Ocugen, Inc.
Direct company coverage
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 Aug 2025 07:00
- Source
- Ocugen, Inc.